Abstract：Cervical cancer is still a common gynecolgical tumor in China. Radical surgery is often the first choice for the treatment of early stage cervical cancer (FIGO stage ⅠB‐ⅡA), and postoperative pathological examination often has adverse prognostic factors affecting the survival. According to the NCCN guidelines, patients with cervical cancer who meet Sedlis criteria and have intermediate‐risk factors (lymphatic vascular space involvement, tumor size or deep interstitial infiltration) are recommended to receive concurrent chemotherapy with postoperative pelvic external irradiation ± cisplatin. However, the diagnostic criteria, indications and methods of adjuvant therapy for patients with intermediate risk factors after early cervical cancer surgery are still controversial. In this article, research progress on the definition of intermediate risk factors for early cervical cancer after radical hysterectomy and adjuvant treatment was mainly reviewed.
Sun Yang,Chen Ya'nan. Research progress on the definition of intermediate risk factors and postoperative adjuvant therapy for early cervical cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(10): 961-965.
[1] Erratum: Global cancerstatistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2020,70(4):313. DOI: 10.3322/caac.21609. [2] Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017,28(suppl_4):iv72-iv83. DOI: 10.1093/annonc/mdx220. [3] NCCN. The NCCN Cervical Cancer Clinical Practice Guidelines in Oncology(version 1,2021)[S/OL].( 2020-10-02)[2021-03-05].https: //www. nccn. org/. [4] Delgado G, Bundy B, Zaino R, et al.Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a gynecologic oncology group study[J]. Gynecol Oncol, 1990,38(3):352-357. DOI: 10.1016/0090-8258(90)90072-s. [5] Stolnicu S, Park KJ, Kiyokawa T, et al.Tumor typing of endocervical adenocarcinoma: contemporary review and recommendations from the international society of gynecological pathologists[J]. Int J Gynecol Pathol, 2021,40(Suppl 1):S75-S91. DOI: 10.1097/PGP.000000000000 0751. [6] Suzuki K, Nagao S, Narita M, et al.Survival impact of adjuvant concurrent chemoradiotherapy after radical hysterectomy in FIGO stage IIIC1 cervical adenocarcinoma[J]. Int J Clin Oncol, 2021,26(7):1322-1329. DOI: 10.1007/s10147-021-01904-0. [7] Ryu SY, Kim MH, Nam BH, et al.Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean gynecologic oncology group study[J]. Br J Cancer, 2014,110(2):278-285. DOI: 10.1038/bjc.2013.716. [8] Satabongkoch N, Khunamornpong S, Pongsuvareeyakul T, et al.Prognostic value of tumor budding in early-stage cervical adenocarcinomas[J]. Asian Pac J Cancer Prev, 2017,18(6):1717-1722. DOI: 10.22034/APJCP.2017.18.6.1717. [9] Huang B, Cai J, Xu X, et al.High-grade tumor budding stratifies early-stage cervical cancer with recurrence risk[J]. PLoS One, 2016,11(11):e0166311. DOI: 10.1371/journal.pone.0166311. [10] Park JY, Chong GO, Park JY, et al.Tumor budding in cervical cancer as a prognostic factor and its possible role as an additional intermediate-risk factor[J]. Gynecol Oncol, 2020,159(1):157-163. DOI: 10.1016/j.ygyno.2020.07.030. [11] Bedell SM, Hedberg C, Griffin A, et al.Role of adjuvant radiation or re-excision for early stage vulvar squamous cell carcinoma with positive or close surgical margins[J]. Gynecol Oncol, 2019,154(2):276-279. DOI: 10.1016/j.ygyno.2019.05.028. [12] McCann GA, Taege SK, Boutsicaris CE, et al. The impact of close surgical margins after radical hysterectomy for early-stage cervical cancer[J]. Gynecol Oncol, 2013,128(1):44-48. DOI: 10.1016/j.ygyno.2012.10.028. [13] 中国抗癌协会妇科肿瘤专业委员会. 子宫颈癌诊断与治疗指南(2021年版)[J].中国癌症杂志,2021,31(6):474-489. DOI: 10.19401/j.cnki.1007-3639.2021.06.06. Chinese Anti‐Cancer Association Gynecologic Oncology Committee. Cervic cancer diagnosis and treatment guidelines (2021 edition)[J].Chin J Cancer,2021,31(06):474‐489. [14] Sedlis A, Bundy BN, Rotman MZ, et al.A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study[J]. Gynecol Oncol, 1999,73(2):177-183. DOI: 10.1006/gyno.1999.5387. [15] Rotman M, Sedlis A, Piedmonte MR, et al.A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study[J]. Int J Radiat Oncol Biol Phys, 2006,65(1):169-176. DOI: 10.1016/j.ijrobp.2005.10.019. [16] Cibula D, Abu-Rustum NR, Fischerova D, et al.Surgical treatment of "intermediate risk" lymph node negative cervical cancer patients without adjuvant radiotherapy-a retrospective cohort study and review of the literature[J]. Gynecol Oncol, 2018,151(3):438-443. DOI: 10.1016/j.ygyno.2018.10.018. [17] Akilli H, Tohma YA, Bulut AN, et al.Comparison of no adjuvant treatment and radiotherapy in early-stage cervical carcinoma with intermediate risk factors[J]. Int J Gynaecol Obstet, 2020,149(3):298-302. DOI: 10.1002/ijgo.13147. [18] Chopra S.et al. Phase III randomized trial of postoperative adjuvant conventional radiation (3dcrt) versus image guided intensity modulated radiotherapy (ig‐imrt) in cervical cancer (parcer): final analysis[J]. Int J Radiat Oncol, Biol, Phys, 2020,108(3S): S1‐S2. [19] Mazonakis M, Lyraraki E, Damilakis J.Lifetime radiation-induced sarcoma risk in patients subjected to IMRT or VMAT for uterine cervix carcinoma[J]. Phys Eng Sci Med, 2021,44(2):573-579. DOI: 10.1007/s13246-021-01002-5. [20] Small W, Bosch WR, Harkenrider MM, et al.NRG oncology/RTOG consensus guidelines for delineation of clinical target volume for intensity modulated pelvic radiation therapy in postoperative treatment of endometrial and cervical cancer: an update[J]. Int J Radiat Oncol Biol Phys, 2021,109(2):413-424. DOI: 10.1016/j.ijrobp.2020.08.061. [21] Yuce Sari S, Guler OC, Gultekin M, et al.Adjuvant small pelvic radiotherapy in patients with cervical cancer having intermediate risk factors only - is it sufficient?[J]. Oncol Res Treat, 2017,40(9):523-527. DOI: 10.1159/000476037. [22] Yeo RM, Chia YN, Namuduri RP, et al.Tailoring adjuvant radiotherapy for stage IB-IIA node negative cervical carcinoma after radical hysterectomy and pelvic lymph node dissection using the GOG score[J]. Gynecol Oncol, 2011,123(2):225-229. DOI: 10.1016/j.ygyno.2011.06.040. [23] Tang Q, Tu YQ, Chen JH, et al.[Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors][J]. Zhonghua Zhong Liu Za Zhi, 2018,40(6):462-466. DOI: 10.3760/cma.j.issn.0253-3766.2018.06.012. [24] Zhao H, Xie C. Phase III randomized trial of comparing chemoradiotherapy vs. radiotherapy alone in lymph node negative patients with early‐stage cervical cancer following radical hysterectomy[J]. Gynecol Oncol, 2019, 54:279‐280. [25] Kim H, Park W, Kim YS, et al.Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor[J]. J Gynecol Oncol, 2020,31(3):e35. DOI: 10.3802/jgo.2020.31.e35. [26] Weng D, Wang H, Zhu C, et al. Randomized trial of adjuvant chemotherapy versus concurrent chemoradiotherapy in early‐stage cervical cancer after radical surgery: a Chinese gynecologic oncology group study (CSEM‐002)[J]. Gynecol Oncol, 2018,149: 30‐30. [27] Matsuo K, Shimada M, Yokota H, et al.Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer[J]. Oncotarget, 2017,8(63):106866-106875. DOI: 10.18632/oncotarget.22437. [28] Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri[J]. Int J Gynaecol Obstet, 2018,143 Suppl 2:22-36. DOI: 10.1002/ijgo.12611. [29] 庄晴晴, 王常玉. 新辅助化疗与单纯手术在局部晚期宫颈癌患者中的疗效对比分析[J].现代妇产科进展,2016,25(7):7-10. DOI: 10.13283/j.cnki.xdfckjz.2016.07.002. Zhuang QQ, Wang CY.Comparative analysis of neoadjuvant chemotherapy plus surgery versus surgery in local advanced cervical cancer[J].2016,25(7):7-10. DOI: 10.13283/j.cnki.xdfckjz.2016.07.002.
2022, Vol. 31 
